



NDA 21-402/S-017

Abbott Laboratories
Attention: Kelly Kaleck-Schlinsog
Manager, Global Pharmaceutical Regulatory Affairs
Dept. PA76/Building AP30-1E
200 Abbott Park Road
Abbott Park, IL 60064-6157

Dear Ms. Kaleck-Schlinsog:

Please refer to your supplemental new drug application dated March 28, 2008, received March 28, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Synthroid (levothyroxine sodium) Tablets.

We also refer to our supplement request letter dated September 28, 2007, in which you were asked to add information to the package insert regarding the drug-drug interaction between orlistat and levothyroxine.

This "Changes Being Effected" supplemental new drug application provides for the addition of the information requested in our supplement request letter dated September 28, 2007.

We have completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Julie Marchick, Regulatory Project Manager, at (301) 796-1280.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Package Insert

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Mary Parks
7/14/2008 02:48:52 PM